Balchem Corp Stock Price, News & Analysis

Balchem Corporation (NASDAQ:BCPC) has announced its acquisition of Cardinal Associates Inc., known as Bergstrom Nutrition, a leading producer of methylsulfonylmethane (MSM) based in Vancouver, Washington. This strategic purchase enhances Balchem's product portfolio, particularly in joint health, sports nutrition, and beauty sectors. Bergstrom's OptiMSM^® is recognized for its quality, holding a U.S. GRAS designation. The integration aims to accelerate growth and expand marketplace opportunities in Balchem's Human Nutrition and Health segment, aligning with its focus on longevity and performance.

Balchem Corporation (NASDAQ: BCPC) reported a strong second quarter for 2022, with net earnings of $29.8 million, up 31% from $22.7 million in Q2 2021. Adjusted net earnings rose to $34.4 million, reflecting a 13.3% increase year-over-year. Record net sales reached $236.7 million, marking a 17.0% growth, driven by Human, Animal, and Specialty Nutrition segments. The company completed the acquisition of Kappa Bioscience, enhancing its portfolio in the nutrition sector. Operational cash flow was robust at $48.2 million.

Balchem Corporation (NASDAQ: BCPC) will hold a conference call on July 29, 2022, at 11:00 AM ET to discuss its second quarter results, which will be published before market opening on the same day. CEO Ted Harris and CFO Martin Bengtsson will lead the call. Participants can access the conference by calling toll-free 1-877-407-8289. A replay will be available from two hours post-conclusion until August 12, 2022, using conference ID #13731403. For more information, visit www.balchem.com.

Balchem Corporation (NASDAQ:BCPC) has successfully completed its acquisition of Kappa Bioscience AS, a leading manufacturer of specialty vitamin K2, enhancing its portfolio in the human nutrition sector. This acquisition, initially announced on June 14, 2022, aims to capitalize on the growing demand for vitamin K2, which is vital for bone health, heart health, and immunity. Kappa's K2VITAL® is recognized for its purity and stability, backed by strong intellectual property and clinical research.

Balchem Corporation (NASDAQ:BCPC) announced the acquisition of Kappa Bioscience AS for an enterprise value of NOK 3.175B (approximately USD 338M). Kappa specializes in vitamin K2, essential for bone and heart health. This acquisition enhances Balchem's portfolio in science-based nutrients, expected to be accretive to earnings per share in 2022. Kappa's projected 2022 revenue is approximately NOK 500M (USD 53M). The deal will strengthen Balchem's market presence in Europe and the U.S., while Kappa will benefit from Balchem's established distribution network.

Balchem Corporation (NASDAQ: BCPC) reported a strong first quarter of 2022, with net earnings of $28.9 million and record net sales of $228.9 million, up 23.3% from the previous year. Adjusted net earnings rose to $33.4 million, reflecting a 17.3% increase, with earnings per share reaching $1.03. All three business segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—experienced double-digit sales growth. Despite rising operational costs, the company maintained solid profit margins and plans to further enhance its sustainability efforts.

Balchem Corporation (BCPC) has announced a conference call on April 29, 2022, at 11:00 AM ET, to discuss first-quarter results. The financial results will be released earlier that day before the market opens. CEO Ted Harris and CFO Martin Bengtsson will host the call, which can be accessed via toll-free number 1-877-407-8289. A replay will be available after the call until May 13, 2022. Balchem operates three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, delivering solutions across various industries.

Balchem Corporation (NASDAQ: BCPC) reported a strong fourth quarter for 2021, achieving net earnings of $24.9 million, up 12.6% from $22.2 million in Q4 2020. Record net sales reached $213.1 million, reflecting a 17.9% increase year-over-year. For the full year, net earnings totaled $96.1 million, up 13.6% from 2020. The adjusted EBITDA for Q4 was $45.6 million, representing a 4.7% increase. The company's segments—Human Nutrition, Animal Nutrition, and Specialty Products—all recorded sales growth. A dividend of $0.64 per share signifies stable financial management.